X | ||||||||||
- Definition Number of products approved by FDA. No definition available.
|
X | ||||||||||
- Definition Number of plasma collection facilities having FDA license. No definition available.
|
X | ||||||||||
- Definition Number of plasma collection facilities under various stages of development. No definition available.
|
X | ||||||||||
- Definition Production cycle from procurement of raw materials to commercial release of finished product. No definition available.
|
X | ||||||||||
- Definition The amount of difference between current assets and liabilities. No definition available.
|
X | ||||||||||
- Definition Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|